Skip to content

Annelies Cannaert

Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg 460, 9000, Ghent, Belgium.

4 papers in the library · 72 citations · publishing 2019-2023

Papers

In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor

Archives of Toxicology July 5, 2020 Eline Pottie, Annelies Cannaert, Christophe P. Stove 36 citations

Serotonergic psychedelics, which act mainly through the serotonin 2A receptor, make up many new psychoactive substances. A stable cell-based bioassay using HEK 293 T cells was developed to monitor β-arrestin 2 recruitment to the 5-HT2AR. After verifying its performance against a transient transfection system, the assay was used to test 30 phenylalkylamine psychedelics: 12 phenethylamine derivatives (2C-X), 7 phenylisopropylamines (DOx), and 11 N-benzylderivatives (25X-NB). The resulting potency and efficacy values confirm findings from other in vitro assays and show a significant correlation with estimated common doses. This approach offers pharmacological insights and may help prioritize legal actions regarding the most potent compounds.

Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances

Analytical Chemistry November 14, 2019 Eline Pottie, Annelies Cannaert, Katleen van Uytfanghe et al. 29 citations

Classic hallucinogens, which activate the serotonin 2A receptor (5-HT2AR), represent the third largest category of new psychoactive substances. A new bioassay was developed that measures receptor activation by monitoring β-arrestin2 recruitment using a split-luciferase system. The assay determined potency and efficacy for various hallucinogens, including LSD, 5-MeO-DALT, mescaline, and several 2C compounds and their NBOMe derivatives, with EC50 values ranging from subnanomolar (NBOMes) to micromolar (mescaline) levels. When applied to plasma screening, blank samples showed pronounced receptor activation due to endogenous serotonin, confirmed by its elimination with a 5-HT2AR antagonist or MAO-A treatment, and by LC-HRMS analysis. The bioassay's main application is characterizing poorly understood serotonergic hallucinogens, as MAO-A metabolism of some compounds could bias detection in biofluids.

Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.

Archives of toxicology May 1, 2023 Marie H Deventer, Mattias Persson, Antonio Laus et al. 7 citations

Some psychedelic substances that carry the N-benzyl phenethylamine (NBOMe) structure can activate the µ opioid receptor (MOR), an off-target effect confirmed by two different assays. This activation was blocked by the opioid antagonist naloxone, indicating these NBOMes bind to the same opioid binding pocket as conventional opioids. Molecular docking showed plausible interactions of 25I-NBOMe with MOR similar to those of opioids. However, MOR activation occurred only at high concentrations, making relevant opioid toxicity in vivo unlikely at physiologically relevant levels. Small modifications to the NBOMe structure could yield more potent MOR agonists with dual MOR/5-HT2A activation potential.